Aspen Neuroscience
- Company typePrivate
- Founded2018
- HeadquartersSan Diego, United States
- Headcount101–250
- GTM typeB2C
- OfferingServices
Aspen Neuroscience firmographics
Firmographics- Name
- Aspen Neuroscience
- Legal name
- Aspen Neuroscience, Inc.
- Website
- https://aspenneuroscience.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Aspen Neuroscience industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA)
Keywords
Where Aspen Neuroscience is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Aspen Neuroscience business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Autologous Cell Therapy Commercialization: Aspen Neuroscience is a pre-revenue clinical-stage company developing personalized autologous iPSC-derived cell therapies. The primary revenue stream will come from commercialization of ANPD001 (sasineprocel) for Parkinson's disease treatment upon FDA approval. The company is preparing for commercial launch with the appointment of a Chief Commercial Officer and expansion of manufacturing capabilities.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Aspen Neuroscience product offering
Product offeringCore offering
Aspen Neuroscience develops personalized autologous cell replacement therapies derived from a patient's own induced pluripotent stem cells (iPSCs), beginning with ANPD001 (Sasineprocel) for moderate-to-advanced Parkinson's disease. The therapy uses patient skin cells converted to iPSCs, differentiated into dopaminergic neuron precursors, and administered via image-guided intracranial injection to the putamen without immunosuppression. Manufacturing is conducted at a 22,000 sq. ft. GMP facility in San Diego with proprietary machine-learning-based genomic quality controls at every stage.
Product overview
Aspen Neuroscience is a clinical-stage regenerative medicine biotechnology company developing personalized autologous iPSC-derived cell replacement therapies. The company's lead product is ANPD001, now officially named Sasineprocel, an autologous dopaminergic neuronal precursor cell therapy for Parkinson's disease. The therapy is manufactured using a proprietary platform that converts patient skin cells to iPSCs, then differentiates them into dopamine-producing neurons, administered via image-guided intracranial injection. The company operates GMP manufacturing facilities in San Diego and is conducting the ASPIRO Phase 1/2a clinical trial with plans for Phase 3 advancement.
Differentiator
Problem solved
Functional benefit
Brands
- Sasineprocel (ANPD001): Autologous iPSC-derived dopaminergic neuron precursor cell (DANPC) therapy for Parkinson's disease; replaces lost dopamine-producing neurons via image-guided intracranial injection without requiring immunosuppressive drugs
Products and services
- ANPD001 (Sasineprocel) Autologous dopaminergic neuronal precursor cell (DANPC) therapy derived from the patient's own iPSCs for the treatment of moderate-to-advanced Parkinson's disease, administered via image-guided intracranial injection to the putamen without requiring immunosuppression. Most advanced autologous investigational cell therapy for Parkinson's in the United States, with FDA Fast Track designation and Phase 1/2a ASPIRO trial underway.
Quantifiable outcome
- Mean Good ON time increased by +2.1 to +2.4 hours at 12 months post-treatment
- +5 more outcomes
Companies that use Aspen Neuroscience
Customer profileSegments1 record
Ideal customer profiles1 record
Aspen Neuroscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Aspen Neuroscience partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- MytoscoreManufacturing collaboration to automate production of dopaminergic neuronal precursor cells (DANPCs) for ANPD001. Mytos provides automated cell manufacturing platform to help Aspen scale production and treat greater numbers of patients.
- Cell X TechnologiescoreCollaboration and license agreement to advance automation of the iPSC stage of Aspen's autologous manufacturing platform. Cell X leads development of its Celligent platform including Cx Suite and Colonyze, while Aspen leverages its bioinformatics-based platform and leads all discovery, preclinical, development, and commercialization activities.
- ClearPoint (MRI-guided Navigation System)coreClearPoint Navigation System used for MRI-guided precision implantation of ANPD001 in the ASPIRO clinical trial, enabling sub-millimeter accuracy in cell transplantation.
- Rune LabsminorPartnership to incorporate active digital health monitoring in the Trial-Ready Screening Cohort Study using Rune Labs' software and data analytics for precision neurology.
- Emerald InnovationsminorPartnership to incorporate passive digital health monitoring using Emerald Innovations' invisible off-body sensors for measuring health analytics in Parkinson's disease patients.
Scale indicators9 records
Recent moves9 records
Expansion highlights6 records
Aspen Neuroscience competitors and assessment
Company assessmentEmerging players
- Century Therapeutics: Century Therapeutics is an emerging cell therapy company developing iPSC-derived allogeneic immune cell therapies for cancer. While focused on oncology, it represents a comparable peer in iPSC-derived engineered cell therapy manufacturing and platform development.
- Fate Therapeutics: Fate Therapeutics is a clinical-stage cell therapy company developing iPSC-derived off-the-shelf NK and T-cell therapies. Comparable as a peer for iPSC-based cell therapy platforms, GMP manufacturing of engineered cell products, and clinical/commercial readiness for novel modalities.
- Sana Biotechnology: Sana Biotechnology is developing engineered cell therapies, including iPSC-derived platforms, for cancer and other diseases. Comparable as a peer advancing iPSC-based platforms toward clinical and commercial scale with deep manufacturing and QC expertise.
- Lineage Cell Therapeutics: Lineage Cell Therapeutics (formerly BioTime, which acquired Asterias) develops allogeneic cell transplant therapies including OPC1 for spinal cord injury and programs for CNS indications. Comparable as a peer in CNS cell therapy clinical translation with shared scientific lineage to historical stem cell programs.
- Sumitomo Pharma: Sumitomo Pharma (with Kyoto University/CiRA researchers) is developing an iPSC-derived dopaminergic neuron cell therapy for Parkinson's disease in Japan. It represents an emerging global competitor in autologous/allogeneic PD cell therapy with strong academic backing and clinical activity in Asia.
- Nkarta: Nkarta is a clinical-stage cell therapy company developing allogeneic and autologous NK cell therapies for cancer. Comparable as an emerging peer in cell therapy manufacturing, GMP operations, and clinical pipeline development.
Others
- Lonza Group: Lonza is a leading contract manufacturer of cell and gene therapies with cell therapy-specific manufacturing services. Aspen's CTO Kim Raineri previously led Lonza cell therapy operations. Relevant as an enabler/infrastructure peer for scalable autologous and allogeneic cell therapy manufacturing rather than a direct product competitor.
Broad incumbents
- Bayer AG (Cell & Gene Therapy): Bayer acquired BlueRock Therapeutics in 2019 to build a cell therapy franchise including Parkinson's disease, and operates AskBio and other gene/cell therapy assets. As the parent of Aspen's closest direct peer, it competes broadly in the same therapeutic and modality space with far greater resources.
- Vertex Pharmaceuticals (Cell Therapy): Vertex has built a cell therapy program including VX-880 for type 1 diabetes (originally developed by Semma Therapeutics using stem cell-derived islet cells). While targeting a different indication, Vertex demonstrates the commercial viability of stem cell-derived autologous/allogeneic cell therapies at scale.
Direct peers
- BlueRock Therapeutics: BlueRock Therapeutics (acquired by Bayer for ~$1B in 2019) is the most direct competitor, developing iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease. Both companies target the same indication with stem cell-derived neuron replacement, but BlueRock pursues an off-the-shelf allogeneic approach versus Aspen's autologous model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Aspen Neuroscience social profiles
Digital presenceAspen Neuroscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aspen Neuroscience leadership team
Management profileNumber of profiles
Profiles13 records
Aspen Neuroscience funding detail
Funding detailFunding overview
Funding rounds6 records
Investors25 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aspen Neuroscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aspen Neuroscience
What does Aspen Neuroscience do?
Aspen Neuroscience develops personalized autologous cell replacement therapies derived from a patient's own induced pluripotent stem cells (iPSCs), beginning with ANPD001 (Sasineprocel) for moderate-to-advanced Parkinson's disease. The therapy uses patient skin cells converted to iPSCs, differentiated into dopaminergic neuron precursors, and administered via image-guided intracranial injection to the putamen without immunosuppression. Manufacturing is conducted at a 22,000 sq. ft. GMP facility in San Diego with proprietary machine-learning-based genomic quality controls at every stage.
Is Aspen Neuroscience a public or private company?
Aspen Neuroscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aspen Neuroscience founded?
Aspen Neuroscience was founded in 2018. It employs 101 to 250 people.
Where is Aspen Neuroscience based?
Aspen Neuroscience is headquartered in San Diego, United States, in the North America region.
How does Aspen Neuroscience make money?
One revenue line is on record: autologous Cell Therapy Commercialization.
Who are Aspen Neuroscience's main competitors?
Emerging players on record are Century Therapeutics, Fate Therapeutics, Sana Biotechnology, Lineage Cell Therapeutics, Sumitomo Pharma and Nkarta. Lonza Group is listed as an others. Broad incumbents are Bayer AG (Cell & Gene Therapy) and Vertex Pharmaceuticals (Cell Therapy). BlueRock Therapeutics is listed as a direct peer.
Does Aspen Neuroscience have an API?
No public API is recorded for Aspen Neuroscience.
What industry is Aspen Neuroscience in?
Aspen Neuroscience's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 541714 and its SIC code is 2836.